

Anira Iqbal, MD

Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH

Vinni Makin, MBBS, MD

Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Hypoglycemia after bariatric surgery: Management updates

ABSTRACT

Bariatric procedures have been shown to decrease mortality in patients with obesity and even induce remission of type 2 diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea. One common complication of bariatric surgery is hypoglycemia, which can be observed months to years later and can significantly impact patient lifestyle. No medications are currently approved for this indication. In this article, we discuss the treatment options available and being studied for post-bariatric surgery hypoglycemia (PBH).

KEY POINTS

PBH typically occurs more than 12 months after bariatric surgery, with symptoms presenting 1 to 3 hours after eating. Symptoms that occur in a fasting state, nocturnal hypoglycemia, or exercise-induced hypoglycemia are less likely to be PBH.

Use of continuous glucose monitors and a food diary while tracking symptoms may assist in diagnosis, although the limitations of false lows and variable sensitivity should be considered when evaluating data from continuous glucose monitors.

Off-label medications to treat PBH are currently widely available (acarbose, diazoxide, nifedipine, verapamil), with other agents on the horizon, including glucagon pumps, avexitide, and insulin receptor antibodies.

Surgical intervention by reversal of gastric bypass or with gastric pouch restriction is considered a last resort.

BARIATRIC PROCEDURES decrease long-term mortality in patients with obesity and even induce remission of type 2 diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea.¹⁻³ Given these benefits, more patients are choosing to undergo bariatric procedures to lose weight, and clinicians now encounter an increasing number of patients, both inpatient and outpatient, with a history of bariatric surgery. Hypoglycemia is a common complication of bariatric surgery that can be observed months to years after surgery.⁴⁻¹⁰ Up to one-third of patients who underwent bariatric surgery reported symptoms of hypoglycemia during mixed meal challenges, while oral glucose tolerance testing has detected a variable incidence of 9.1% to 32.8%.⁴⁻⁶

A recently published meta-analysis of data from studies that assessed post-bariatric surgery hypoglycemia (PBH) by continuous glucose monitoring showed that more than 50% of individuals who had undergone bariatric surgery exhibited hypoglycemia.⁷ Although these data may overestimate the rate of PBH, given the frequent false lows documented with use of continuous glucose monitors (CGMs), they underscore the high burden of hypoglycemia in this population. Hypoglycemia can be debilitating when symptomatic and has unknown consequences when asymptomatic. With the increased frequency of patients presenting with reported hypoglycemia, especially as continuous glucose monitoring becomes more common, diagnosing hypoglycemia, determining its cause, and knowing the available treatment options are imperative to tailor therapy and improve patient lifestyle.

doi:10.3949/ccjm.92a.24033

The approach to PBH was thoroughly outlined in the review by Millstein and Lawler⁸ in 2017. In this article, we discuss advances made since then and briefly summarize treatment options that are currently available as well as those being studied.

■ DIAGNOSIS

The diagnosis of hypoglycemia is based on the Whipple triad, which consists of the following⁸:

- Low glucose measured in a blood sample
- Concurrent symptoms of hypoglycemia (palpitations, shakiness, sweating, anxiety, irritability, dizziness, hunger)
- Reversal of symptoms when low blood glucose is corrected.

PBH typically occurs more than 1 year after bariatric surgery and is more severe in patients undergoing Roux-en-Y gastric bypass (RYGB) surgery compared with sleeve gastrectomy, although the incidence remains similar.^{4,9,10} Risk factors for PBH other than the RYGB procedure include female sex, lower preoperative body mass index and hemoglobin A1c, lower fasting glucose, lower glucose during the oral glucose tolerance test, and greater weight loss at 6 months.⁹ The symptoms of PBH typically occur 1 to 3 hours after eating, and neuroglycopenic symptoms (behavioral changes, confusion, impaired cognitive function, seizure, loss of consciousness) are seen in severe hypoglycemia.

Symptoms that occur less than 6 to 12 months after surgery, in the fasting state, or less than 1 hour or more than 4 hours after eating are less likely to be PBH. In patients who report any of these, other causes for hypoglycemia should be explored through complete history, physical examination, and laboratory testing.⁹ Differentials include dumping syndrome, side effects from medications (sulfonylureas, meglitinides, insulin use), hypothyroidism, hypoglycemia due to malnutrition, adrenal insufficiency, liver dysfunction, insulinoma, and insulin antibody syndrome, among others.

Dumping syndrome is quite common after bariatric surgery and typically occurs soon after surgery, while the onset of PBH can take years.¹¹ The symptoms of the 2 conditions are similar, but dumping syndrome occurs within 1 hour after eating vs 1 to 3 hours after eating with PBH.¹¹ It has been postulated that dumping syndrome and PBH are part of the same spectrum, known as early and late dumping syndrome, respectively.

Patients should be encouraged to check their fingerstick glucose at home during episodes before self-treating and to keep a food diary to document the timing of hypoglycemia in relation to food intake. An oral glucose

tolerance test may provoke symptoms of severe dumping syndrome and should not be used. The mixed meal tolerance test is a more natural and helpful diagnostic tool but is laborious and can precipitate symptoms.⁹

■ CONTINUOUS GLUCOSE MONITORING

A healthy person typically spends less than 1.1% of their time in a state of hypoglycemia (glucose < 70 mg/dL).¹² Continuous glucose monitoring for diagnosis of hypoglycemia in patients without diabetes has not been approved and should be used cautiously because CGMs have poor specificity for low interstitial glucose, leading to high false-positive rates, which can promote anxiety. Inaccurate readings can result from calibration errors, error margin (mean absolute relative difference), the position of sensors, interference from certain medications, humidity and extreme temperature, skin changes, and compression of sensors (if the patient lies on the site of the sensor).¹³

CGMs can assess the timing of symptoms in relation to interstitial glucose levels (with a typical lag time of some minutes) and association with food and can unveil asymptomatic or nocturnal hypoglycemia. The newer CGMs (eg, Dexcom G6 or G7, Freestyle Libre 3) are more accurate than those of previous generations. CGMs have greater sensitivity and specificity in diagnosing PBH than the mixed meal tolerance test, but a study comparing CGMs and fingerstick glucose monitoring has not been done.^{14,15} Continuous glucose monitoring has been associated with reductions in both hypoglycemia and hyperglycemia in the PBH population, likely because it helps patients detect glycemic variability, allowing dietary modification and self-treatment to avoid hypoglycemia.¹⁶

Recently, the Dexcom Stelo was approved by the US Food and Drug Administration as the first over-the-counter CGM for patients without diabetes, followed by Abbott's Lingo, although cost and insurance coverage may remain a barrier.^{17,18}

■ PATHOPHYSIOLOGY

Meal-induced gut factors (glucose-dependent insulinotropic polypeptide, glucagon-like peptide [GLP] 1, direct neural factors, and nutrient factors) regulate glucose homeostasis after food intake. Secretion of gut factors after a meal induces a robust pancreatic beta-cell secretory response.¹⁹ Alterations in the anatomy of patients following bariatric surgery leads to accelerated emptying of nutrients into the intestine, bypassing the stomach and allowing for earlier, more rapid absorption of glucose, which causes an earlier and

TABLE 1
Medications for managing post-bariatric surgery hypoglycemia: Mechanisms of action

Medication	Mechanism of action
Acarbose ^{8,23,25,26}	Inhibits intestinal alpha-glucosidase—delays absorption of glucose from the intestine, decreases postprandial glycemic and insulinemic peaks
Diazoxide ^{26–28}	Reduces insulin secretion by inhibition of beta-cell adenosine triphosphate-sensitive potassium channels, induces hepatic gluconeogenesis
Octreotide, pasireotide ^{25,26,29}	Somatostatin analogs delay gastric emptying, reduce insulin and GLP-1 secretion
Nifedipine or verapamil ^{25,30}	Inhibits insulin release by inhibiting calcium channels in pancreatic beta cells
GLP-1 analogs ^{25,26,31}	Decreases variability in GLP release, which causes synchronous insulin and glucose peaks, delays gastric emptying, decreases appetite, stimulates glucagon secretion
Dipeptidyl peptidase 4 inhibitors ^{25,26}	Reduces the degradation of GLP-1 and glucose-dependent insulintropic polypeptide and raises their levels
GLP-1 antagonist ^{32–34}	Prevents surges in GLP-1 and insulin, increases glucagon secretion
SGLT-2 inhibitors ^{35,36}	Reduces carbohydrate absorption by inhibiting intestinal SGLT-1 and increasing hepatic glucose production
Interleukin 1 beta antagonist (anakinra) ³⁷	Decreases dysregulated proinflammatory signaling, which can cause excessive insulin response
Glucagon ^{38,39}	Glucagon receptor agonist, stimulates glycogenolysis and hepatic gluconeogenesis
Insulin receptor antibody (XOMA 358) ^{40,41}	Reverses insulin-induced hypoglycemia by significantly decreasing insulin sensitivity and increasing hepatic glucose output

GLP = glucagon-like peptide; SGLT = sodium-glucose cotransporter

greater rise in peak postprandial glucose. This results in increased GLP-1 release from the intestine, which induces increased insulin release from the pancreas and a subsequent drop in blood glucose.^{8,9}

Thus, postprandial hypoglycemia after RYGB is typically attributed to the combined effects of more rapid nutrient transit from the gastric pouch to the gut and the enhanced incretin effect. Salehi et al²⁰ reported that continuous infusion of the GLP-1 receptor antagonist avexitide (exendin 9-39) reduced the meal-induced insulin response in patients without diabetes who had undergone RYGB compared with patients who did not undergo surgery.

Other factors that may impact PBH are a decreased glucagon response to hypoglycemia, postoperative increased insulin sensitivity, and decreased insulin clearance.¹⁹ An increase in beta-cell mass after surgery (nesidioblastosis) was initially thought to contribute,

but a subsequent analysis revealed no difference in overall beta-cell mass in patients with PBH compared with autopsy samples from obese and lean individuals.²¹ Moreover, pancreatectomy has not been found to always be curative.

Use of alcohol or medications such as beta-blockers, some fluoroquinolones, nonsteroidal anti-inflammatory drugs, and sulfonylureas has been documented to worsen hypoglycemia.²²

MEDICAL MANAGEMENT

Dietary modifications are the cornerstone of PBH management. Frequent small, nutrient-dense meals rich in protein and low-glycemic foods and low in carbohydrates (15–30 g per meal) are recommended.⁸ Healthy fats should be included to compensate for the lower carbohydrate content. Pure carbohydrates

TABLE 2
Medications for managing post-bariatric surgery hypoglycemia: Dosages and side effects

Medication	Dosage	Side effects	Notes
Acarbose ^{8,23,25,26}	25 mg with 1 meal per day, slowly titrate up to 100 mg at every meal daily	Bloating, abdominal cramping, diarrhea	Used as first line because it's affordable and available Not recommended in significant renal impairment If hypoglycemia occurs, correct with simple carbohydrates (glucose, dextrose, honey)—complex carbohydrates (table sugar, juice, soft drink, candy) will not be effective
Diazoxide ^{26–28}	50–100 mg twice daily to start	Fluid retention, edema, nausea, hypotension, hirsutism, headache	Consider dose reduction with renal impairment Typically used for hypoglycemia from insulinomas Affordability and insurance coverage are barriers
Octreotide, pasireotide ^{25,26,29}	Octreotide 25–100 µg SC before meals Octreotide long-acting repeatable 20-mg intramuscular injection monthly Pasireotide 50–300 µg SC before meals or 300 µg SC daily	Diarrhea, steatorrhea, cholelithiasis, hyperglycemia (more with pasireotide), QT prolongation	Safe to use in renal impairment Expensive Screening abdominal ultrasonography and electrocardiogram required Pasireotide is longer acting than octreotide and is available for compassionate use in severe PBH Oral octreotide is available but has not been used for this indication
Nifedipine or verapamil ^{25,30}	Verapamil 40 mg 3 times daily Nifedipine 30–60 mg daily	Hypotension, edema	Safe to use in renal impairment
GLP-1 analogs ^{25,26,31}	Liraglutide 0.6 mg titrated to 1.2 mg SC daily, up to 1.8 mg daily	Nausea, constipation	Contraindicated in patients with family or personal history of medullary thyroid carcinoma Use with caution in patients with history of pancreatitis Safe to use in renal impairment but avoid dehydration Expensive
Dipeptidyl peptidase 4 inhibitors ^{25,26}	Sitagliptin 100 mg once daily	Nausea, constipation	Inconclusive results—not recommended
GLP-1 antagonist ^{32–34}	Avexotide 30 mg SC twice daily	Headache, nausea, injection-site reaction	Recently granted breakthrough therapy designation by the US Food and Drug Administration for treating PBH and congenital hyperinsulinism, currently in phase 3 trial
SGLT-2 inhibitors ^{35,36}	Canagliflozin 100 or 300 mg daily Empagliflozin 10–25 mg daily	Dehydration, urinary tract and genital mycotic infections, euglycemic diabetic ketoacidosis	Dosage adjustment required in renal impairment Canagliflozin and empagliflozin shown to improve glycemic response to oral glucose tolerance and mixed meal tolerance tests, respectively, in patients with PBH
Interleukin 1 beta antagonist ³⁷	Anakinra 100 mg SC daily		Anakinra and SGLT-2 inhibitor empagliflozin reduced the number of hypoglycemic events during a liquid mixed meal test
Glucagon ^{38,39}	Dasiglucagon 80 or 120 µg SC injection as needed for hypoglycemia	Nausea, vomiting, hyperglycemia, reduced appetite	Still under clinical investigation, use of glucagon in an insulin pump has shown satisfactory results May be used for treatment of acute severe hypoglycemia
Insulin receptor antibody ^{40,41}	XOMA 358 3–9 mg/kg daily	Headache, hyperhidrosis	Results from phase 2 trial not announced yet

GLP = glucagon-like peptide; SC = subcutaneous; PBH = post-bariatric surgery hypoglycemia; SGLT = sodium-glucose cotransporter

without protein or fat should be avoided as this can precipitate severe hyperglycemia.²³ Avoiding excessive caffeine and alcohol, which can cause hypoglycemia via inhibition of hepatic glucose release, is also important. Commercial products containing uncooked cornstarch, which degrades slowly in the intestines and is absorbed slowly, are reported to be helpful.²⁴ However, sustaining strict dietary modifications can be difficult for patients.

Patients with PBH should treat their hypoglycemia with a simple carbohydrate combined with protein or fat, as they will often have recurrent hypoglycemia if a simple carbohydrate is used alone.

No medications are currently approved for management of refractory PBH, but several medications are used off-label (**Table 1** and **Table 2**).^{8,23,25-41} In a comparative study on the effect of acarbose, sitagliptin, verapamil, liraglutide, and pasireotide on PBH after RYGB, acarbose and pasireotide reduced postprandial hypoglycemia in persons with PBH.²⁵ Acarbose appeared to have a glucose-stabilizing effect, reducing peak postprandial hyperglycemia. Glucocorticoids have been used off-label to prevent hypoglycemia, but because of the possibility of causing iatrogenic Cushing syndrome, use for this indication is not recommended.⁸

SURGICAL OPTIONS

In cases of nutrition- and medication-refractory severe hypoglycemia or complicated malnutrition management, enteral nutrition through a gastrostomy tube placed into the remnant stomach or jejunum should be considered.⁴²

Surgical options, considered a last alternative due to risks and complications, include RYGB reversal, RYGB conversion to sleeve gastrectomy, and gastric pouch restriction.⁴³ If gastric bypass reversal is being

considered, a trial of solely remnant stomach tube feeds (with no oral intake) should be pursued first. If this ameliorates hypoglycemia, then gastric bypass reversal may be of benefit.⁸ Partial or complete pancreatectomy has been performed for this indication, but owing to a high rate of hypoglycemia recurrence and poor success rate, it is no longer recommended.^{44,45}

CONCLUSION

While bariatric surgery is an excellent treatment for obesity and its complications, the long-term repercussions of recurrent hypoglycemia may lead to impaired quality of life, motor-vehicle accidents, cardiovascular events, and regain of body weight (due to overcompensation by overeating). Thus, it is important to treat PBH with currently available agents concomitantly with dietary changes. CGM use should be considered in these patients as a mode of intervention, when possible, although it is important to consider the limitations of false measured lows.

Medications currently widely available to use off-label include acarbose, diazoxide, nifedipine, and verapamil. Other medications such as GLP-1 agonists, sodium-glucose cotransporter 2 inhibitors, dasiglucagon, octreotide, and pasireotide can be used off-label when available. Agents on the horizon include glucagon pumps, avexotide, and insulin-receptor antibodies. Surgical intervention by reversal of gastric bypass or with gastric pouch restriction is considered a last alternative. ■

DISCLOSURES

Dr. Makin has disclosed teaching and speaking for Bayer. Dr. Iqbal reports no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

REFERENCES

- Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass. *N Engl J Med* 2017; 377(12):1143–1155. doi:10.1056/NEJMoa1700459
- Singh AK, Singh R, Kota SK. Bariatric surgery and diabetes remission: who would have thought it? *Indian J Endocrinol Metab* 2015; 19(5):563–576. doi:10.4103/2230-8210.163113
- Adams TD, Meeks H, Fraser A, et al. Long-term all-cause and cause-specific mortality for four bariatric surgery procedures. *Obesity (Silver Spring)* 2023; 31(2):574–585. doi:10.1002/oby.23646
- Lee CJ, Clark JM, Schweitzer M, et al. Prevalence of and risk factors for hypoglycemic symptoms after gastric bypass and sleeve gastrectomy. *Obesity (Silver Spring)* 2015; 23(5):1079–1084. doi:10.1002/oby.21042
- Raverdy V, Baud G, Pigeyre M, et al. Incidence and predictive factors of postprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: a five year longitudinal study. *Ann Surg* 2016; 264(5):878–885. doi:10.1097/SLA.0000000000001915
- Belligoli A, Sanna M, Serra R, et al. Incidence and predictors of hypoglycemia 1 year after laparoscopic sleeve gastrectomy. *Obes Surg* 2017; 27(12):3179–3186. doi:10.1007/s11695-017-2742-2
- Lupoli R, Lembo E, Rainone C, et al. Rate of post-bariatric hypoglycemia using continuous glucose monitoring: a meta-analysis of literature studies. *Nutr Metab Cardiovasc Dis* 2022; 32(1):32–39. doi:10.1016/j.numecd.2021.08.047
- Millstein R, Lawler HM. Hypoglycemia after gastric bypass: an emerging complication. *Cleve Clin J Med* 2017; 84(4):319–328. doi:10.3949/ccjm.84a.16064
- Salehi M, Vella A, McLaughlin T, Patti ME. Hypoglycemia after gastric bypass surgery: current concepts and controversies. *J Clin Endocrinol Metab* 2018; 103(8):2815–2826. doi:10.1210/jc.2018-00528
- Capristo E, Panunzi S, De Gaetano A, et al. Incidence of hypoglycemia after gastric bypass vs sleeve gastrectomy: a randomized trial. *J Clin Endocrinol Metab* 2018; 103(6):2136–2146. doi:10.1210/jc.2017-01695
- van Furth AM, de Heide LJM, Emous M, Veeger N, van Beek AP. Dumping syndrome and postbariatric hypoglycemia: supporting evidence for a common etiology. *Surg Obes Relat Dis* 2021; 17(11):1912–1918. doi:10.1016/j.soard.2021.05.020
- Shah VN, DuBose SN, Li Z, et al. Continuous glucose monitoring profiles in healthy nondiabetic participants: a multicenter prospective study [published correction appears in *J Clin Endocrinol Metab* 2022; 107(4):e1775–e1776]. *J Clin Endocrinol Metab* 2019; 104(10):4356–4364. doi:10.1210/jc.2018-02763

13. Facchinetti A, Del Favero S, Sparacino G, Castle JR, Ward WK, Cobelli C. Modeling the glucose sensor error. *IEEE Trans Biomed Eng* 2014; 61(3):620–629. doi:10.1109/TBME.2013.2284023
14. Halperin F, Patti ME, Skow M, Bajwa M, Goldfine AB. Continuous glucose monitoring for evaluation of glycemic excursions after gastric bypass. *J Obes* 2011; 2011:869536. doi:10.1155/2011/869536
15. Kefurt R, Langer FB, Schindler K, Shakeri-Leidenmüller S, Ludvik B, Prager G. Hypoglycemia after Roux-en-Y gastric bypass: detection rates of continuous glucose monitoring (CGM) versus mixed meal test. *Surg Obes Relat Dis* 2015; 11(3):564–569. doi:10.1016/j.soard.2014.11.003
16. Cummings C, Jiang A, Sheehan A, et al. Continuous glucose monitoring in patients with post-bariatric hypoglycaemia reduces hypoglycaemia and glycaemic variability. *Diabetes Obes Metab* 2023; 25(8):2191–2202. doi:10.1111/dom.15096
17. US Food and Drug Administration. FDA clears first over-the-counter continuous glucose monitor. March 10, 2023. <https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor>. Accessed January 8, 2025.
18. Abbott. Abbott receives US FDA clearance for two new over-the-counter continuous glucose monitoring systems. June 10, 2024. <https://abbott.mediaroom.com/2024-06-10-Abbott-Receives-U-S-FDA-Clearance-for-Two-New-Over-the-Counter-Continuous-Glucose-Monitoring-Systems>. Accessed January 8, 2025.
19. Salehi M, Gastaldelli A, D'Alessio DA. Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia. *J Clin Endocrinol Metab* 2014; 99(6):2008–2017. doi:10.1210/jc.2013-2686
20. Salehi M, Gastaldelli A, D'Alessio DA. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. *Gastroenterology* 2014; 146(3):669–680.e2. doi:10.1053/j.gastro.2013.11.044
21. Meier JJ, Butler AE, Galasso R, Butler PC. Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. *Diabetes Care* 2006; 29(7):1554–1559. doi:10.2337/dc06-0392
22. Ben Salem C, Fathallah N, Hmouda H, Bouraoui K. Drug-induced hypoglycaemia: an update. *Drug Saf* 2011; 34(1):21–45. doi:10.2165/11538290-000000000-00000
23. Bantle JP, Ikramuddin S, Kellogg TA, Buchwald H. Hyperinsulinemic hypoglycemia developing late after gastric bypass [published correction appears in *Obes Surg* 2007; 17(7):996]. *Obes Surg* 2007; 17(5):592–594. doi:10.1007/s11695-007-9102-6
24. Lembo E, Lupoli R, Ciciola P, et al. Implementation of low glycemic index diet together with cornstarch in post-gastric bypass hypoglycemia: two case reports. *Nutrients* 2018; 10(6):670. doi:10.3390/nu10060670
25. Øhrstrøm CC, Worm D, Højager A, et al. Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. *Diabetes Obes Metab* 2019; 21(9):2142–2151. doi:10.1111/dom.13796
26. Rossini G, Risi R, Monte L, et al. Postbariatric surgery hypoglycemia: nutritional, pharmacological and surgical perspectives. *Diabetes Metab Res Rev* 2024; 40(2):e3750. doi:10.1002/dmrr.3750
27. Gonzalez-Gonzalez A, Delgado M, Fraga-Fuentes MD. Use of diazoxide in management of severe postprandial hypoglycemia in patient after Roux-en-Y gastric bypass. *Surg Obes Relat Dis* 2013; 9(1):e18–e19. doi:10.1016/j.soard.2011.05.010
28. Chen X, Feng L, Yao H, Yang L, Qin Y. Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: a systematic review and meta-analysis. *PLoS One* 2021; 16(2):e0246463. doi:10.1371/journal.pone.0246463
29. de Heide LJM, Wouda SHT, Peters VJT, et al. Medical and surgical treatment of postbariatric hypoglycaemia: Retrospective data from daily practice. *Diabetes Obes Metab* 2023; 25(3):735–747. doi:10.1111/dom.14920
30. Ames A, Lago-Hernandez CA, Grunvald E. Hypoglycemia after gastric bypass successfully treated with calcium channel blockers: two case reports. *J Endocr Soc* 2019; 3(7):1417–1422. doi:10.1210/je.2019-00097
31. Abrahamsson N, Engström BE, Sundbom M, Karlsson FA. GLP1 analogs as treatment of postprandial hypoglycemia following gastric bypass surgery: a potential new indication? *Eur J Endocrinol* 2013; 169(6):885–889. doi:10.1530/EJE-13-0504
32. Craig CM, Lawler HM, Lee CJE, et al. PREVENT: a randomized, placebo-controlled crossover trial of avexitide for treatment of postbariatric hypoglycemia. *J Clin Endocrinol Metab* 2021; 106(8):e3235–e3248. doi:10.1210/clinem/dgab103
33. Tan M, Lamendola C, Luong R, McLaughlin T, Craig C. Safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9-39) for treatment of post-bariatric hypoglycaemia. *Diabetes Obes Metab* 2020; 22(8):1406–1416. doi:10.1111/dom.14048
34. Amylyx Pharmaceuticals. Amylyx Pharmaceuticals announces pivotal phase 3 LUCIDITY trial design for GLP-1 receptor antagonist Avexitide in post-bariatric hypoglycemia. December 4, 2024. <https://www.amylyx.com/news/amlyx-pharmaceuticals-announces-pivotal-phase-3-lucidity-trial-design-for-glp-1-receptor-antagonist-avexitide-in-post-bariatric-hypoglycemia>. Accessed January 8, 2025.
35. Ciudin A, Sánchez M, Hernandez I, et al. Canagliflozin: a new therapeutic option in patients that present postprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: a pilot study. *Obes Facts* 2021; 14(3):291–297. doi:10.1159/000515598
36. Carpentieri GB, Gonçalves SEAB, Casagrande MZ, Mourad WM, Pinto LGC, Zanella MT. SGLT2 inhibition with empagliflozin as a possible therapeutic option for postprandial hypoglycemia after bariatric surgery. *Obes Surg* 2022; 32(8):2664–2671. doi:10.1007/s11695-022-06119-4
37. Hepprich M, Wiedemann SJ, Schelker BL, et al. Postprandial hypoglycemia in patients after gastric bypass surgery is mediated by glucose-induced IL-1β. *Cell Metab* 2020; 31(4):699–709.e5. doi:10.1016/j.cmet.2020.02.013
38. Nielsen CK, Øhrstrøm CC, Kielgast UL, et al. Dasiglucagon effectively mitigates postbariatric postprandial hypoglycemia: a randomized, double-blind, placebo-controlled, crossover trial. *Diabetes Care* 2022; 45(6):1476–1481. doi:10.2337/dc21-2252
39. Mulla CM, Zavitsanou S, Laguna Sanz AJ, et al. A randomized, placebo-controlled double-blind trial of a closed-loop glucagon system for postbariatric hypoglycemia. *J Clin Endocrinol Metab* 2020; 105(4):e1260–e1271. doi:10.1210/clinem/dgz197
40. Johnson KW, Neale A, Gordon A, et al. Attenuation of insulin action by an allosteric insulin receptor antibody in healthy volunteers. *J Clin Endocrinol Metab* 2017; 102(8):3021–3028. doi:10.1210/jc.2017-00822
41. Johnson K. Single administration of XOMA 358, an insulin receptor attenuator, improves post-meal and nighttime hypoglycemia profiles in post gastric bypass hypoglycemia (PGBH) patients. https://xoma.com/wp/wp-content/uploads/2017/08/ENDO-2017_Oral.pdf. Accessed January 8, 2025.
42. Zanley E, Shah ND, Craig C, Lau JN, Rivas H, McLaughlin T. Guidelines for gastrostomy tube placement and enteral nutrition in patients with severe, refractory hypoglycemia after gastric bypass. *Surg Obes Relat Dis* 2021; 17(2):456–465. doi:10.1016/j.soard.2020.09.026
43. Mala T. Postprandial hyperinsulinemic hypoglycemia after gastric bypass surgical treatment. *Surg Obes Relat Dis* 2014; 10(6):1220–1225. doi:10.1016/j.soard.2014.01.010
44. Vanderveen KA, Grant CS, Thompson GB, et al. Outcomes and quality of life after partial pancreatectomy for noninsulinoma pancreatogenous hypoglycemia from diffuse islet cell disease. *Surgery* 2010; 148(6):1237–1246. doi:10.1016/j.surg.2010.09.027
45. Eisenberg D, Azagury DE, Ghiassi S, Grover BT, Kim JJ. ASMBs position statement on postprandial hyperinsulinemic hypoglycemia after bariatric surgery. *Surg Obes Relat Dis* 2017; 13(3):371–378. doi:10.1016/j.soard.2016.12.005

Address: Anira Iqbal, MD, Department of Endocrinology, Diabetes and Metabolism, F20, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; aniraiqbal93@gmail.com